Qternmet XR (dapagliflozin/saxagliptin/metformin) / AstraZeneca - LARVOL DELTA

Stability Indicating HPLC method Development and Validation for Simultaneous estimation of Metformin, Dapagliflozin and Saxagliptin in Bulkdrug and Pharmaceutical Dosage Form. (PubMed, Biomed Chromatogr) - "The product was found to degrade significantly in oxidative, acid and base hydrolysis degradation conditions and the degradation products were well resolved from the active peaks, thus proving the stability-indicating power of the method. The developed and validated stability-indicating RP-HPLC method was appropriate for quantitative determination of these drugs in pharmaceutical preparations and also quality control in bulk manufacturing."

Journal

Bioequivalence and Food Effect of Dapagliflozin/Saxagliptin/Metformin Extended-release Fixed-combination Drug Products Compared With Coadministration of the Individual Components in Healthy Subjects. (PubMed, Clin Ther) - P1 | "These data support the use of the dapagliflozin/saxagliptin/metformin XR FCDP in patients with T2DM. ClinicalTrials.gov identifier: NCT03169959."

Clinical • Journal • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Dapagliflozin plus saxagliptin add-on to metformin reduces liver fat and adipose tissue volume in patients with type 2 diabetes. (PubMed, Diabetes Obes Metab) - P3b; "Dapagliflozin plus saxagliptin significantly decreased liver fat and adipose tissue volume versus glimepiride, and reduced serum liver enzyme levels, indicating a favorable metabolic profile of dapagliflozin plus saxagliptin in patients with T2D on metformin therapy. ClinicalTrials."

Clinical • Journal • MRI